Systematic Reviews
Copyright ©The Author(s) 2021.
World J Meta-Anal. Jun 28, 2021; 9(3): 297-308
Published online Jun 28, 2021. doi: 10.13105/wjma.v9.i3.297
Table 2 Patient arm characteristics


Baseline characteristics


Gender
Ethnic origin







OAD at screening
Ref.
Arms
M (%)/F (%)
White (%)
Black (%)
Asian (%)
Other (%)
Age (yr)
Bodyweight
BMI (kg/ m2)
Duration of Diabetes (yr)
HbA1 (%)
Hb (mmol/mol)
FPG (mmol/L)
Metformin
Metformin plus pioglitazone
Sulphonylurea
Other
Lingvay et al[25]Degludec/liraglutide (n = 278)51.4/48.694.22.23.20.458.488.331.711.648.4NA8.9NANANANA
Glargine (n = 279)49.1/50.995.01.83.20.059.187.331.711.338.2NA8.9NANANANA
Rosenstock et al[26]LixiLan (n = 161)49.7/50.398.1NANANA56.990.132.26.38.1649.8YesNANANA
Gla-100 (n = 162)52.5/47.598.8NANANA56.691.632.07.18.0649.5YesNANANA
Rosenstock et al[28]iGlarLixi (n = 469)47.3/52.788.97.01.72.358.2NA31.68.98.1659.9YesNA55.2Glinide, Sodium glucose co-transporter inhibitor, dipeptidyl dipeptidase 4 inhibitor
iGlar (n = 467)50.7/49.390.17.11.51.358.3NA31.78.78.1659.8YesNA53.3
Lixi (n = 234)56.8/43.292.35.11.31.358.7NA32.08.98.1659.8YesNA52.6
All (n = 1170)50.6/49.490.16.71.51.758.4NA31.78.88.1659.8YesNA53.9